Biopharma Leaders Unite To Stand With Science LEARN MORE Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints LEARN MORE BioNTech and Pfizer Initiate Rolling Submission to EMA for BNT162b2 LEARN MORE Alibaba Cloud, Fintech Academy and Pfizer Partner to Accelerate Healthcare Innovations LEARN MORE LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer LEARN MORE RECENT PRESS RELEASES 27/02/2020 - Mylan and Pfizer Finalize Appointments to Viatris Board of Directors 25/02/2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 18/02/2020 - European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) 11/02/2020 - XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC 31/01/2020 - Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab) 28/01/2020 - PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS 23/01/2020 - Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults 23/01/2020 - PFIZER’S GREENSTONE AND DIGITAL MEN’S HEALTH CLINIC ROMAN COLLABORATE TO OFFER PATIENTS REMOTE ACCESS TO THE ONLY FDA-APPROVED AUTHORIZED GENERIC VERSION OF VIAGRA® (SILDENAFIL CITRATE) 06/01/2020 - BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Current page 8
